Physician profile
Stephen L Smith
NPI 1255444386
$2,467.39
in general payments reported to CMS, 2019-2025
28 companies · $18.44 in 2025
The $18.44 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $148 · 2021: $214 · 2022: $429 · 2023: $674 · 2024: $687 · 2025: $18.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $529.73 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $493.57 | 2022-2024 | Vraylar, Qulipta, Ubrelvy |
| Exact Sciences Corporation | $198.34 | 2023-2024 | Cologuard Collection Kit |
| Alkermes, INC. | $175.29 | 2019-2023 | Vivitrol |
| Astrazeneca Pharmaceuticals Lp | $140.63 | 2019-2024 | Breztri |
| Pfizer INC. | $99.03 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $89.99 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $80.23 | 2021-2022 | |
| Indivior INC. | $69.61 | 2022-2024 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.02 | 2019-2024 | Xifaxan |
| Lilly USA, LLC | $57.45 | 2021-2024 | Mounjaro, Jardiance |
| Viiv Healthcare Company | $55.32 | 2024 | Apretude |
| Amarin Pharma, INC. | $52.65 | 2019-2021 | |
| Abbott Laboratories | $50.29 | 2021-2022 | |
| Amgen INC. | $46.27 | 2024 | Otezla, Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $39.85 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.72 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $31.59 | 2023 | Gemtesa |
| Hologic Sales and Service, LLC | $27.13 | 2019 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Scynexis, INC. | $16.53 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.59 | 2024 | Caplyta |
| Braeburn INC. | $15.32 | 2023 | Brixadi |
| Merck Sharp & Dohme LLC | $14.38 | 2022 | |
| Boston Scientific Corporation | $13.85 | 2021 | |
| Eisai INC. | $13.50 | 2020 | |
| Mylan Specialty L.P. | $12.73 | 2019 | |
| Forte Bio-Pharma LLC | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.